Rodriguez E
Eur J Immunol. 2025; 55(3):e202451318.
PMID: 40071681
PMC: 11898543.
DOI: 10.1002/eji.202451318.
Zielinska M, Ciazynska M, Sulejczak D, Rutkowski P, Czarnecka A
Biomolecules. 2025; 15(2).
PMID: 40001572
PMC: 11853485.
DOI: 10.3390/biom15020269.
Sang M, Ge J, Ge J, Tang G, Wang Q, Wu J
Front Immunol. 2025; 15:1382842.
PMID: 39911580
PMC: 11794490.
DOI: 10.3389/fimmu.2024.1382842.
Bakker N, Garner H, van Dyk E, Champanhet E, Klaver C, Duijst M
NPJ Breast Cancer. 2025; 11(1):5.
PMID: 39843922
PMC: 11754814.
DOI: 10.1038/s41523-025-00721-2.
Yang M, Zhou J, Lu L, Deng D, Huang J, Tang Z
Exploration (Beijing). 2024; 4(6):20230171.
PMID: 39713208
PMC: 11655317.
DOI: 10.1002/EXP.20230171.
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective.
Pezzicoli G, Musci V, Ciciriello F, Salonne F, Cafforio P, Lionetti N
Ther Adv Med Oncol. 2024; 16:17588359241298500.
PMID: 39563719
PMC: 11574901.
DOI: 10.1177/17588359241298500.
P-stalk ribosomes act as master regulators of cytokine-mediated processes.
Dopler A, Alkan F, Malka Y, van der Kammen R, Hoefakker K, Taranto D
Cell. 2024; 187(24):6981-6993.e23.
PMID: 39437780
PMC: 11896023.
DOI: 10.1016/j.cell.2024.09.039.
A Study of Disease Prognosis in Lung Adenocarcinoma Using Single-Cell Decomposition and Immune Signature Analysis.
Lee C, Wu Y, Liao T, Hsiao S, Hsu J, Chang T
Cancers (Basel). 2024; 16(18).
PMID: 39335178
PMC: 11431002.
DOI: 10.3390/cancers16183207.
Non-small-cell lung cancer.
Hendriks L, Remon J, Faivre-Finn C, Garassino M, Heymach J, Kerr K
Nat Rev Dis Primers. 2024; 10(1):71.
PMID: 39327441
DOI: 10.1038/s41572-024-00551-9.
Integrated noninvasive diagnostics for prediction of survival in immunotherapy.
Yeghaian M, Bodalal Z, Tareco Bucho T, Kurilova I, Blank C, Smit E
Immunooncol Technol. 2024; 24:100723.
PMID: 39185322
PMC: 11342748.
DOI: 10.1016/j.iotech.2024.100723.
Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion.
Lapuente-Santana O, Sturm G, Kant J, Ausserhofer M, Zackl C, Zopoglou M
iScience. 2024; 27(8):110529.
PMID: 39161957
PMC: 11331718.
DOI: 10.1016/j.isci.2024.110529.
Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry.
Poalelungi D, Neagu A, Fulga A, Neagu M, Tutunaru D, Nechita A
J Pers Med. 2024; 14(7).
PMID: 39063947
PMC: 11278211.
DOI: 10.3390/jpm14070693.
Immunotherapy in breast cancer: A clinician's perspective.
Chaudhuri S, Thomas S, Munster P
J Natl Cancer Cent. 2024; 1(2):47-57.
PMID: 39035768
PMC: 11256727.
DOI: 10.1016/j.jncc.2021.01.001.
Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts.
Szadai L, Bartha A, Pla Parada I, Lakatos A, Pal D, Lengyel A
Front Oncol. 2024; 14:1428182.
PMID: 39015503
PMC: 11249723.
DOI: 10.3389/fonc.2024.1428182.
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.
Kamaraj R, Ghosh S, Das S, Sen S, Kumar P, Majumdar M
Bioconjug Chem. 2024; 35(8):1089-1115.
PMID: 38990186
PMC: 11342303.
DOI: 10.1021/acs.bioconjchem.4c00253.
Ribosome specialization in cancer: a spotlight on ribosomal proteins.
Ramalho S, Dopler A, Faller W
NAR Cancer. 2024; 6(3):zcae029.
PMID: 38989007
PMC: 11231584.
DOI: 10.1093/narcan/zcae029.
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.
Kulesza A, Couty C, Lemarre P, Thalhauser C, Cao Y
J Pharmacokinet Pharmacodyn. 2024; 51(6):581-604.
PMID: 38904912
PMC: 11795844.
DOI: 10.1007/s10928-024-09930-x.
PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
Pei F, He W, Duan Y, Yao Q, Zhao Y, Fan X
Cancer Med. 2024; 13(12):e7224.
PMID: 38888366
PMC: 11184646.
DOI: 10.1002/cam4.7224.
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
Kundu M, Butti R, Panda V, Malhotra D, Das S, Mitra T
Mol Cancer. 2024; 23(1):92.
PMID: 38715072
PMC: 11075356.
DOI: 10.1186/s12943-024-01990-4.
Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.
Sun B, Chen L, Lei Y, Zhang L, Sun T, Liu Y
Br J Radiol. 2024; 97(1159):1320-1327.
PMID: 38711192
PMC: 11186562.
DOI: 10.1093/bjr/tqae087.
